Lifecore Biomedical, Inc. reported a significant decline in financial performance for the three months ended March 31, 2026, with total revenues of $23.2 million, down 34% from $35.2 million in the comparable period of February 23, 2025. The decrease was primarily driven by a 48% drop in revenues from hyaluronic acid (HA) manufacturing, which fell to $7.4 million from $14.4 million, attributed to reduced demand from a key customer. Contract development and manufacturing organization (CDMO) revenues also decreased by 24%, totaling $15.8 million, due to lower sales volumes and the completion of discrete development projects in the prior period. The gross profit for the quarter was $4.5 million, representing a 55% decline from $9.8 million, with a gross profit margin of 19.2%, down from 28.0%.
In terms of operational changes, Lifecore has made strategic improvements, including the installation of a fully automated high-speed aseptic isolator filler in September 2024 and the implementation of a new enterprise resource planning (ERP) system in January 2026. These initiatives are aimed at enhancing manufacturing efficiency and inventory control. The company also reported a reduction in operating expenses, which totaled $9.1 million, down 52% from $18.9 million in the previous year, largely due to decreased research and development costs and lower selling, general, and administrative expenses.
Lifecore's financial position remains under scrutiny, with total liabilities increasing to $204.7 million as of March 31, 2026, compared to $198.1 million at the end of 2025. The company reported a net loss of $15.0 million for the quarter, slightly higher than the $14.8 million loss in the prior period. The increase in interest expense, particularly related to the term loans from Alcon, contributed to the overall loss. As of the end of the reporting period, Lifecore had cash and cash equivalents of $20.8 million and $17.3 million available under its revolving credit facility, indicating a solid liquidity position.
Looking ahead, Lifecore is focused on improving operational efficiencies and productivity through further procurement and operational strategies. The company anticipates that the new ERP system will bolster financial management and reduce costs as it continues to grow. Lifecore's management has expressed confidence in its ability to navigate the current market conditions and is committed to enhancing its manufacturing capabilities while maintaining compliance with financial covenants under its credit agreements. The company is also preparing for potential redemptions of its Redeemable Convertible Preferred Stock, which could impact its liquidity and capital requirements in the near future.
About LIFECORE BIOMEDICAL, INC. DE
Lifecore Biomedical is a contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceuticals and medical devices. It produces hyaluronic acid and viscous non-HA products, offering formulation, aseptic filling, and supply chain services across global markets. The company leverages proprietary fermentation, advanced manufacturing, and regulatory expertise to serve biopharmaceutical and biotech clients with high-quality, complex injectable solutions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.